Compare EHI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 191.1M |
| IPO Year | 2003 | 2001 |
| Metric | EHI | CGEN |
|---|---|---|
| Price | $5.85 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 84.3K | ★ 252.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $1.30 |
| 52 Week High | $6.70 | $3.24 |
| Indicator | EHI | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 52.66 |
| Support Level | $5.80 | $2.20 |
| Resistance Level | $5.93 | $2.54 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 58.33 | 68.18 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.